Esther J J Habets1, Linda Dirven1, Ruud G Wiggenraad1, Antoinette Verbeek-de Kanter1, Geert J Lycklama À Nijeholt1, Hanneke Zwinkels1, Martin Klein1, Martin J B Taphoorn1. 1. Department of Neurology, Medical Center Haaglanden, The Hague, the Netherlands (E.J.J.H., H.Z., M.J.B.T.); Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands (L.D., M.J.B.T.); Radiotherapy Center West, The Hague, the Netherlands (R.G.W., A.V.-d.K.); Department of Radiology, Medical Center Haaglanden, The Hague, the Netherlands (G.J.L.àN.); Department of Medical Psychology, VU University Medical Center, Amsterdam, the Netherlands (M.K.).
Abstract
BACKGROUND: Stereotactic radiotherapy (SRT) is expected to have a less detrimental effect on neurocognitive functioning and health-related quality of life (HRQoL) than whole-brain radiotherapy. To evaluate the impact of brain metastases and SRT on neurocognitive functioning and HRQoL, we performed a prospective study. METHODS: Neurocognitive functioning and HRQoL of 97 patients with brain metastases were measured before SRT and 1, 3, and 6 months after SRT. Seven cognitive domains were assessed. HRQoL was assessed with the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and BN20 questionnaires. Neurocognitive functioning and HRQoL over time were analyzed with linear mixed models and stratified for baseline Karnofsky performance status (KPS), total metastatic volume, and systemic disease. RESULTS: Median overall survival of patients was 7.7 months. Before SRT, neurocognitive domain and HRQoL scores were lower in patients than in healthy controls. At group level, patients worsened in physical functioning and fatigue at 6 months, while other outcome parameters of HRQoL and cognition remained stable. KPS < 90 and tumor volume >12.6 cm(3) were both associated with worse information processing speed and lower HRQoL scores over 6 months time. Intracranial tumor progression was associated with worsening of executive functioning and motor function. CONCLUSIONS: Prior to SRT, neurocognitive functioning and HRQoL are moderately impaired in patients with brain metastases. Lower baseline KPS and larger tumor volume are associated with worse functioning. Over time, SRT does not have an additional detrimental effect on neurocognitive functioning and HRQoL, suggesting that SRT may be preferred over whole-brain radiotherapy.
BACKGROUND: Stereotactic radiotherapy (SRT) is expected to have a less detrimental effect on neurocognitive functioning and health-related quality of life (HRQoL) than whole-brain radiotherapy. To evaluate the impact of brain metastases and SRT on neurocognitive functioning and HRQoL, we performed a prospective study. METHODS: Neurocognitive functioning and HRQoL of 97 patients with brain metastases were measured before SRT and 1, 3, and 6 months after SRT. Seven cognitive domains were assessed. HRQoL was assessed with the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and BN20 questionnaires. Neurocognitive functioning and HRQoL over time were analyzed with linear mixed models and stratified for baseline Karnofsky performance status (KPS), total metastatic volume, and systemic disease. RESULTS: Median overall survival of patients was 7.7 months. Before SRT, neurocognitive domain and HRQoL scores were lower in patients than in healthy controls. At group level, patients worsened in physical functioning and fatigue at 6 months, while other outcome parameters of HRQoL and cognition remained stable. KPS < 90 and tumor volume >12.6 cm(3) were both associated with worse information processing speed and lower HRQoL scores over 6 months time. Intracranial tumor progression was associated with worsening of executive functioning and motor function. CONCLUSIONS: Prior to SRT, neurocognitive functioning and HRQoL are moderately impaired in patients with brain metastases. Lower baseline KPS and larger tumor volume are associated with worse functioning. Over time, SRT does not have an additional detrimental effect on neurocognitive functioning and HRQoL, suggesting that SRT may be preferred over whole-brain radiotherapy.
Authors: Minesh P Mehta; May N Tsao; Timothy J Whelan; David E Morris; James A Hayman; John C Flickinger; Michael Mills; C Leland Rogers; Luis Souhami Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-01 Impact factor: 7.038
Authors: John P Kirkpatrick; Zhiheng Wang; John H Sampson; Frances McSherry; James E Herndon; Karen J Allen; Eileen Duffy; Jenny K Hoang; Zheng Chang; David S Yoo; Chris R Kelsey; Fang-Fang Yin Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-21 Impact factor: 7.038
Authors: Eric L Chang; Jeffrey S Wefel; Moshe H Maor; Samuel J Hassenbusch; Anita Mahajan; Frederick F Lang; Shiao Y Woo; Leni A Mathews; Pamela K Allen; Almon S Shiu; Christina A Meyers Journal: Neurosurgery Date: 2007-02 Impact factor: 4.654
Authors: Alexandra S Zimmer; Seth M Steinberg; Dee Dee Smart; Mark R Gilbert; Terri S Armstrong; Eric Burton; Nicole Houston; Nadia Biassou; Brunilde Gril; Priscilla K Brastianos; Scott Carter; David Lyden; Stanley Lipkowitz; Patricia S Steeg Journal: Future Oncol Date: 2020-04-09 Impact factor: 3.404
Authors: Andrea Di Cristofori; Barbara Zarino; Claudia Fanizzi; Giorgia Abete Fornara; Giulio Bertani; Paolo Rampini; Giorgio Carrabba; Manuela Caroli Journal: J Neurooncol Date: 2017-07-06 Impact factor: 4.130
Authors: Grainne M O'Kane; Jie Su; Brandon C Tse; Vivian Tam; Tiffany Tse; Lin Lu; Michael Borean; Emily Tam; Catherine Labbé; Hiten Naik; Nicole Mittmann; Mark K Doherty; Penelope A Bradbury; Natasha B Leighl; Frances A Shepherd; Nadine M Richard; Kim Edelstein; David Shultz; M Catherine Brown; Wei Xu; Doris Howell; Geoffrey Liu Journal: Oncologist Date: 2019-04-05
Authors: Michael T Milano; Veronica L S Chiang; Scott G Soltys; Tony J C Wang; Simon S Lo; Alexandria Brackett; Seema Nagpal; Samuel Chao; Amit K Garg; Siavash Jabbari; Lia M Halasz; Melanie Hayden Gephart; Jonathan P S Knisely; Arjun Sahgal; Eric L Chang Journal: Neuro Oncol Date: 2020-12-18 Impact factor: 12.300
Authors: Nadia N Laack; Stephanie L Pugh; Paul D Brown; Sherry Fox; Jeffrey S Wefel; Christina Meyers; Ali Choucair; Deepak Khuntia; John H Suh; David Roberge; Merideth M Wendland; Deborah Bruner Journal: Neurooncol Pract Date: 2018-12-03